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ABSTRACT
Dopamine is a neurotransmitter which belongs to the catecholamine and phenethylamine
families of organic compounds, and plays an important role in the regulation of reward,
movement, attention, behavior and cognition. Dopamine neurotransmission is marked by the
initiation of its release from the pre-synaptic neurons and the signal is terminated by re-uptake of
dopamine from the synapse. The synaptic concentration of dopamine and therefore, the level
dopamine receptor stimulation is regulated to an extent by the activity of the dopamine
transporter (DAT). DAT is responsible for the uptake of dopamine back into the presynaptic
neuron from the synapse. DAT is known to play a critical role in certain pharmacological or
pathological conditions. For example, DAT is one of the major targets of several
psychostimulant drugs like cocaine and amphetamine. Cocaine competitively inhibits dopamine
uptake by blocking DAT which leads to increased dopamine in the synapse, one of the initial
steps that promote addiction. DAT is also a major target of amphetamine (AMPH), another
powerful stimulating drug. AMPH is used regularly in the treatment of neurodevelopment
disorders such as attention deficit hyperactivity disorder (ADHD) but despite its role as an
effective medication in such disorders, AMPH is more commonly known for its psychostimulant
and addictive properties as a drug of abuse.

AMPH induces its rewarding and addictive properties by acting as a substrate of vesicular
monoamine transporter (VMAT) and plasma membrane monoamine (dopamine, norepinephrine,
and serotonin) transporters. AMPH is similar in structure to monoamines like dopamine,
norepinephrine and therefore can bind and enter the presynaptic neurons via the transporters.
Once in the neuron, AMPH causes an elevation in extracellular monoamine levels by inducing
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vesicular depletion of monoamines and also by promoting reverse transport (efflux) of
monoamines through plasma membrane transporters. Several groups have shown that acute
AMPH treatments alter the function and the number of DAT on the cell membrane but the longterm effects of chronic AMPH exposure have still not been clearly identified. Previous data from
our laboratory suggested that parental AMPH exposure reduces dopamine uptake in C.
elegans dopaminergic neurons isolated from progeny.

In order to determine if the long-term effects caused by AMPH in native C. elegans cultured
neurons is reproducible in human DAT (hDAT) expressing cells, we carried out our initial
investigation in LLC-PK1 porcine kidney epithelial cells stably transfected with hDAT. Cells
were treated with AMPH and then analyzed for dopamine uptake, after the cells had undergone
one, two or three round of division. Results from the experiments showed a significant decrease
in dopamine uptake compared to untreated cells. This suggests that changes caused by AMPH
were conserved up to three cell divisions. These data led us to hypothesize that long term
reduction in dopamine reuptake, as a result of chronic AMPH treatment, is caused by downregulation of DAT.

In our next approach we investigated the long term effect of AMPH in the SH-SY5Y human
neuroblastoma cell lines. Previous studies have shown that the SH-SY5Y cells can be chemically
differentiated into more mature neuron-like phenotype by treatment with retinoic acid (RA).
Thus, we pre-treated cells with AMPH and allowed cells to cross one or more cell divisions
before treating them with RA. Dopamine uptake assays revealed a significant decrease in
dopamine re-accumulation in AMPH-treated cells with respect to control. Results from these
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experiments also revealed NET-mediated dopamine uptake in SH-SY5Y cells. In fact,
desipramine, a specific NET inhibitor, totally blocked the dopamine uptake whereas GBR12909,
which is a specific DAT inhibitor, did not show inhibition. Taken together, these results suggest
that parental AMPH treatment down regulates the expression or activity of catecholamine
transporters such as DAT and NET in daughter cells.
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INTRODUCTION
Neurotransmission
The central nervous system (CNS) in humans is an complex system responsible for processing
information from all parts of the body. The CNS is made up of two kinds of specialized cellsneurons and glia. Neurons are responsible for building up the information processing network in
the brain by forming interconnections in the CNS and receiving, conducting and transmitting
signaling chemicals called neurotransmitters to the synaptic cleft. The synaptic cleft or synapse is
the gap between two neurons where the neurotransmitters are released [1].

Neurons are electrically excitable cells capable of transmitting information through an
electrochemical process. The primary components of a neuron include the soma, axon, and
dendrites. The soma is the spherical part of the neuron that makes up the cell body and is
connected to the axon and smaller tree-like branches called dendrites. The soma is composed of
the nucleus and other important organelles like the Golgi apparatus, ribosomes, mitochondria and
endoplasmic reticulum. Synaptic signals from other neurons are received by the soma and
dendrites whereas signals to other neurons, muscles and glands are sent by the axons. Axons are
nerve fibers which are basically long projections that extend from the soma to the terminal
buttons, more commonly known as axonal terminals. Signals from axons of other neurons are
primarily received by the dendrites which are smaller branched projections from the soma and
are located next to the axons. The axonal terminals contain neurotransmitters and are responsible
for releasing neurotransmitters into the synapse, across which impulses are sent[2].
Neuronal communication builds the foundation of the general function of the CNS where
electrical events propagate a signal within a neuron and chemical processes such as
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neurotransmission send signal from one neuron to another or to muscle cells (Figure 1). Neurons
can communicate within the cell, referred to as ‘intracellular signaling’ and they are also capable
of communicating between cells, known as ‘intercellular signaling’. The conductance of
electrical signals or action potentials along axons is how a neuron achieves long distance, rapid
communication with its own terminals or terminal boutons and the terminal boutons establishes
communication between neurons by the process of neurotransmission[3].

Neurotransmission or synaptic transmission is communication between neurons which begins
when an action potential travels along the axon of a presynaptic neuron and reaches the axon
terminal. During conduction, an action potential can travel at a rate up to 150 meters or roughly
500 feet per second. At the axon terminal, the neuron sends out its output across the synapse to
other neurons[4]. At electrical synapses, the ‘output’ will be an electrical signal and at chemical
synapses, the ‘output’ will be neurotransmitters.
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Image courtesy, http://www.mind.ilstu.edu/curriculum/neurons_intro/imgs/synapses, with
permission
Figure 1: Difference between electrical and chemical synapses

Once an action potential reaches the axon terminal it cannot cross the synaptic space. At the
terminal button, the action potential causes membranous sacs called vesicles to move to the
membrane of the terminal. Concurrently, membrane depolarization takes place which causes the
voltage-dependent calcium (Ca2+) channel on the presynaptic neuron to open and allow Ca2+ to
enter into the cell. Once Ca2+ enters the presynaptic neuron, it binds to the membrane of the
vesicles causing vesicles containing neurotransmitters to deplete and release them into the
synapse. The neurotransmitters then diffuse across the synaptic space and bind to special proteins
called receptors on the post-synaptic neuron. The binding of a neurotransmitter to its receptor
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can trigger an action potential in the post-synaptic neuron[4, 5]. That electrical signal then moves
towards the cell body of the post-synaptic neuron. Once the post-synaptic neuron elicits an action
potential, the neurotransmitter dissociates from its receptor to the synaptic space where it is
either degraded by enzymes in the synapse or translocated back into the pre-synaptic neuron by
transporter proteins. The brief post-synaptic potential produced by neurotransmitters is usually
terminated by their re-uptake (Figure 2). For monoamine transporters like dopamine, serotonin
and norepinephrine post-synaptic potentials are terminated by re-uptake.

Image courtesy,
http://www.macalester.edu/academics/psychology/whathap/ubnrp/meth08/biochemistry/synapse
Figure 2: Illustration of chemical neurotransmission
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Monoamine neurotransmitters
The monoamine family of neurotransmitters includes- dopamine, norepinephrine and serotonin.
Their respective transporters- the dopamine transporter (DAT), the norepinephrine transporter
(NET) and the serotonin transporter (SERT), which are transmembrane proteins are located in
plasma membranes of monaminergic neurons. The monoamine transporters are a major target of
psychostimulant drugs. Structurally, monoamines contain an amino group which is connected to
an aromatic ring by a two carbon chain. Besides being referred to as monoamines, dopamine and
norepinephrine are also addressed as catecholamines as they consist of a catechol group (Figure
3)[6].

Catecholamine is an amine derived from the amino acid tyrosine, examples include epinephrine,
adrenaline, norepinephrine, and dopamine that act as hormones or neurotransmitters. The amino
acid tyrosine is created from phenylalanine by hydroxylation of the enzyme phenylalanine
hydroxylase. Catecholamine-secreting neurons via several reactions convert tyrosine to L-DOPA
and then to dopamine and then based on the cell type dopamine is sometimes further converted
to norepinephrine and eventually to epinephrine[6, 7].

Image courtesy, http://mybrainnotes.com/brain-neurotransmitters-catecholamines
Figure 3: Types of catecholamines
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Dopaminergic system and Noradrenergic system
The dopaminergic system plays an integral role in the regulation of the reward system. When we
are exposed to a rewarding stimulus, the brain responds by increasing release of the
neurotransmitter dopamine. The pathway most often associated with reward is the mesolimbic
dopaminergic pathway which originates in the ventral tegmental area (VTA). As a part of the
reward pathway, dopamine is principally produced in the ventral tegmental area which is
connected to the nucleus accumbens by the mesolimbic dopaminergic pathway. The nucleus
accumbens is situated in the part of the brain that is strongly associated with motivational reward
called the ventral striatum. When we experience something rewarding or use an addictive drug,
dopamine neurons in the VTA are activated. These neurons project to the nucleus accumbens via
the mesolimbic dopamine pathway and their activation causes extracellular dopamine levels in
the nucleus accumbens to rise[8]. Another major dopamine pathway is the mesocortical pathway
which also originates in the VTA and travels to the cerebral cortex specifically to the frontal
lobe. This dopamine pathway is also activated during rewarding experiences and is considered a
part of the reward system[9].

Dopamine neurotransmission is also involved in the regulation of movement and emotional
responses. Deficiency in dopamine can lead to delayed and uncoordinated movement, a clinical
symptom seen in the neurological disease Parkinson’s. The dopaminergic system has been
associated with psychiatric disorders like schizophrenia and attention-deficit hyperactivity
disorder (ADHD) and also mediates extrapyramidal side effects in pathological conditions like
dysphagia[10]. The dopaminergic system is a primary target of drugs of abuse and dopamine
plays an integral role in drug abuse, dependence and addiction[11].
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Dopamine synthesis in the brain involves two enzymes- tyrosine hydroxylase (TH) and amino
acid decarboxylase. Tyrosine is converted to the direct precursor of dopamine, L-DOPA, by TH
and then L-DOPA is converted into dopamine by amino acid decarboxylase. Once synthesized,
dopamine is transported from the cytosol into storage vesicles by vesicular monoamine
transporter (VMAT). Dopamine is stored in these vesicles where it is protected from degradation
by enzymes like monoamine oxidase and catechol-O-methyl transferase. Dopamine is stored in
these storage vesicles until it is released into the synapse in response to physiological stimuli.
Once in the synapse, dopamine binds to and activates dopamine receptors. All of the dopamine
receptors are G-protein coupled receptors and their signaling is primarily mediated by interaction
with and activation of G-proteins. The action in response to dopamine released is terminated by
its reuptake into the presynaptic neuron which is principally regulated by the dopamine
transporter (DAT)[12].

In noradrenergic neurons dopamine is converted to norepinephrine by the action of the enzyme
dopamine-β-hydroxylase and this reaction takes place within the synaptic vesicles.
Norepinephrine, also referred to as noradrenaline, works as both a hormone and a
neurotransmitter, and is predominantly released from the ends of sympathetic nerve fibers
(noradrenergic neurons). Neurons that produce norepinephrine are distributed throughout the
brain stem, most notably in the locus coeruleus. The output of the noradrenergic locus coeruleus
cells projects further throughout the cerebrum, cerebral cortex, thalamic nuclei, cerebellum and
the spinal cord. Due to this broad range of projection paths, norepinephrine is involved in
mediating many behavioral and physiological processes like mood, attention, stress, overall
arousal and sexual behavior[13]. Like dopamine, norepinephrine has also been found to play a
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large role in attention and focus (Figure 4). In neurodevelopment disorders like ADHD,
psychostimulant medications are prescribed to help elevate levels of dopamine and
norepinephrine.

Figure 4: Monoamines and the functions they share[14]

Monoamine Transporters
Transporters like NET, SERT, GABA and DAT belong to the SLC6A gene family. NET, DAT
and SERT are monoamine transporters responsible for regulating the synaptic concentration of
monoamines (norepinephrine, dopamine and serotonin). DAT is a membrane spanning protein
that pumps dopamine out of the synapse and back into cytosol where other vesicle membrane
transporters like VMAT sequester dopamine into vesicles for storage and later release (Figure 5).
Dopamine uptake by DAT provides the primary mechanism in which dopamine is cleared from
synapse although there may be an exception in the frontal cortex where evidence suggests a
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possibly larger role of NET in regulating dopamine uptake[15]. Transporters belonging to
SLC6A gene family translocate neurotransmitters into cells by coupling transport to ion
gradients, for example- DAT is a symporter that moves dopamine across the cell membrane by
coupling the movement to the energetically favorable movement of sodium ions moving from
high to low concentration into the cell. DAT function requires binding and co-transport of 2Na+
ions and one Cl- ion with dopamine substrate. The binding of dopamine and the ions induces
DAT to undergo a conformational change which allows dopamine to unbind on the intracellular
side of the membrane[16].

The activity of DAT promotes regulation of dopamine mediated signals which are involved in
cognition , behavior and also reward. DAT localization and distribution has been found in areas
of the brain which include nigrostriatal, mesolimbic and mesocortical pathways. Previous studies
have shown that functional regulation of DAT is largely accomplished by phosphorylation,
palmitoylation and internalization of the transporter by the kinases, substrate pretreatment and
interaction with presynaptic receptors[17, 18]. DAT is implicated in a number of dopamine
related disorders including ADHD, bipolar disorder, clinical depression, addiction and
alcoholism[19]. Since DAT is largely responsible for the termination of dopamine
neurotransmission, it has a pivotal role in psychostimulant actions induced by stimulating drugs
like cocaine and AMPH. The mechanism behind cocaine mediated inhibition is simple where the
drug binds to the transporter and blocks dopamine uptake but AMPH causes inhibition at the
transporter by binding to the transporter and entering the presynaptic neuron and inducing efflux
of dopamine through DAT.

	
  

9	
  

Image courtesy, Daniela. B et al, Transcranial sonography in movement disorders. The Lancet
Neurology, 2008. Volume 7, No. 11, p1044–1055.
Figure 5: Dopamine neurotransmission and uptake of dopamine by DAT
Like DAT, NET is responsible for clearing off extracellular norepinephrine (NE) from the
synapse and pumping it back into the presynaptic neurons. NET mediated reuptake of NE is
crucial in preventing excess concentration of the neurotransmitter in the synaptic cleft; it is also
pivotal in the removal of norepinephrine from the heart and other peripheral organs like lungs,
liver, kidney and muscles[20]. NE is hypothesized to play a role in psychiatric disorders like
depression and ADHD. Psychostimulants like cocaine and AMPH, and antidepressants like
desipramine, reboxetine and various others, impede the reuptake of norepinephrine via NET and
elevate NE extracellular concentration and potentiate the activation of postsynaptic
receptors[21]. AMPH acts as a substrate of monoamine transporters like NET and induces a
reversal in the direction of neurotransmitter transport (efflux) which results in large accumulation
of synaptic NE. Another important feature of NET is it can transport dopamine as well as NE. In
fact, NET exhibits greater affinity for dopamine than DAT.
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Psychostimulant Drugs
Psychostimulants are drugs that stimulate the brain mostly by causing activation of the
dopaminergic system; besides dopamine, stimulants also may cause release of tremendous
amount of norepinephrine and serotonin. The effect of stimulating drugs on dopamine and
norepinephrine neurotransmission is primarily mediated by these drugs interfering with
neurotransmitter transporter function. DAT and NET are often associated with addiction as they
are high affinity molecular targets of powerful stimulating drugs like cocaine and AMPH[22].
Psychostimulants have varying affinity for different monoamine transporters (DAT, NET,
SERT), for example AMPH and methylphenidate have much lower affinity for SERT compared
to their affinity for DAT and NET. Cocaine has earned the reputation of being one of the most
addictive and dangerous illicit drugs. Cocaine is deemed as a simple inhibitor as it inhibits
monoamine uptake by blocking plasma membrane monoamine transporters-DAT, NET and
SERT[23].

AMPH and methamphetamine are also CNS stimulant drugs that fall under the category of
substrate-type releasers. Releasers like AMPH are more effective in increasing synaptic
concentration of monoamine neurotransmitters as they not only cause competitive inhibition of
reuptake by competing with substrate binding to the transporters but also increase the pool of
neurotransmitters available for release by transporter-mediated exchange. AMPH acts as
substrate of DAT and NET and previous studies have reported the transport of AMPH into the
presynaptic neuron via DAT results in more number of transporters in the inward-facing
conformation which increases the probability of cytosolic dopamine to bind to DAT and exit the
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neuron via reverse transport. Beside AMPH- induced reverse transport, AMPH analogues may
affect monoamine transporters through phosphorylation and transporter trafficking[24, 25].

AMPH is commonly used to treat several disorders, including ADHD, narcolepsy, and obesity.
Prescription AMPHs like Adderall are used to treat ADHD patients. AMPH has proven to be
very effective in treating children, adolescents, and adults diagnosed with ADHD, with
responsiveness rates in the range of 70-80%. Prescription AMPHs are known to induce a
calming and ‘focusing’ effect on individuals diagnosed with ADHD since ADHD patients face
difficulty to pay attention and they are more hyperactive or impulsive than people of their age.

Despite being an effective medication, concerns have been raised about possible cardiovascular
effects with the daily use of prescription AMPH. There have been consistent reports of increase
in mean heart rate and blood pressure following AMPH treatment. This could be due to
peripheral functions of dopamine and norepinephrine. A substantial amount of dopamine
circulates in the bloodstream which is produced by the sympathetic nervous system and is
independent of dopamine synthesis and function in the brain. There are some dopamine receptors
on the walls of arteries and the AMPH mediated increase in dopamine may act through the
sympathetic nervous system to increase heart muscle contraction force and heart rate, thereby
increasing cardiac output and blood pressure.

Addiction to AMPH is also a matter of serious consideration for anyone taking this drug without
medical supervision. When stimulants are prescribed by doctors they begin with low doses and
gradually increase the dose until the therapeutic effect of the stimulant is achieved. The gradual
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increase in dose enables slow and steady increases of dopamine, which are similar to the way
dopamine is naturally produced in the brain. Addiction most likely occurs when stimulants are
taken in doses and via routes other than those prescribed. Unsupervised use of prescription
AMPH can increase brain dopamine in a rapid and highly amplified manner. This rapid rise in
dopamine in the brain disrupts normal communication between brain cells and produce euphoric
like sensation which leads to drug seeking and dependence and increases the risk of
addiction[24]. There is in fact ongoing concern regarding use of stimulants to treat children or
adolescents with ADHD. Stimulants prescribed to treat a child’s or adolescent’s ADHD could
affect an individual’s vulnerability to developing drug and psychiatric problems at a later stage in
life. Recent statistics have shown that the longer the use and abuse of Adderall continues, the
stronger an addiction can become. For example, in the year 2012, almost 16 million prescriptions
were written for Adderall and over 116,000 people were admitted to rehab for an addiction to
Adderall.

Taking these incidences of AMPH abuse and addiction into account we decided to analyze long
term effect of AMPH. Previous studies done in our lab in the model organism C.elegans have
shown that AMPH exposure during embryogenesis induces behavioral changes in adult worms
suggesting that the presence of AMPH during development has a long term effect and we see
consequences at a much later stage in the worm’s life.

Also previous studies have demonstrated that AMPH specifically targets the DAT to promote
dopamine release consequently engaging different classes of dopamine receptors (e.g. the D2
like receptors).
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We investigated how chronic AMPH exposure causes long term effect on dopamine uptake in
cultured cells. For our investigation we used human DAT (hDAT) transfected cell line, the LLCPK1 , and the human neuroblastoma cells, SH-SY5Y, which endogenously expresses hDAT, in
order to test our hypothesis that the ‘long term reduction in DA reuptake, as a result of chronic
AMPH treatment, is caused by down-regulation of DAT.

EXPERIMENTAL METHODS
Cell Cultures
Lewis lung carcinoma-porcine kidney (LLC-PK1) cells
The LLC-PK1 cells are derived from the kidney of a normal, healthy male pig and the cell line
exhibits typical epithelial –like morphology. These pig kidney epithelial cells are widely used in
pharmacologic and metabolic research investigations worldwide.

For our experiments we obtained LLC-PK1 cells which were stably transfected with hDAT
(courtesy of Vaughan and Foster labs). Transfected LLC-PK1 cells were maintained in αmodified Eagle’s medium (AMEM) containing 2 mM L-glutamine, 5% fetal bovine serum
(FBS), 200 µg/mL G418 sulfate and 1X penicillin/streptomycin. Cells were grown in a 5% CO2
incubator at 37°C.

After obtaining hDAT transfected LLC-PK1 cells, we maintained and propagated the cell line in
Minimum Essential Medium (MEM) supplemented with L-Glutamine, Antibacterial and
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Antimycotic (AA) solution, 5% Fetal Bovine Serum (FBS) and 200µg/ml G418. Cells were
grown at 37°C in a 5% CO2 incubator throughout the course of experiments.

SH-SY5Y cells
The human neuroblastoma cell line, SH-SY5Y was originally derived from a bone marrow
biopsy of a neuroblastoma patient. The cell culture contains both adherent and floating cells
where both types are viable. The SH-SY5Y has two morphologically distinct phenotypes- the
neuroblast-like cells (N type) and the epithelial-like cells (S type). Cells with neuroblast-like
phenotype are positive for the presence of catecholaminergic markers as they express tyrosine
hydroxylase and dopamine-β-hydroxylase. Another distinct feature of SH-SY5Y cells is that
they can be chemically differentiated into a more mature neuron-like phenotype using Retinoic
Acid (RA) or phorbol esters such as 12-O-tetradecanoyl-phorbol-13 acetate (TPA). In our
experiments, cells were subjected to only RA-induced differentiation[26].

SH-SY5Y cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM). Medium was
prepared by adding 50% Fetal bovine serum (FBS) and 1% Penicillin and Streptomycin solution
(Pen Strep) in 500ml DMEM. Cells were grown at 37°C in a 5% CO2 incubator.

During the course of the project, both LLC-PK1 and SH-SY5Y cells were passaged according to
the following protocol where after removing media, cells were washed twice with 10ml sterile
1X phosphate buffer saline (1X PBS). After 1X PBS wash, 2ml of 1X trypsin solution was added
to promote cell detachment. Trypsin was removed by aspiration and the cells were incubated in
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37°C incubators for 5 mins to promote cell detachment from the flask. Once cells detached, the
cell suspension was gently mixed with 10 ml DMEM and collected in a 15 ml tube. Cell pellets
were collected by centrifugation (at 1500 rpm and 4°C for 5 mins). Cells pellets were resuspended in 1ml fresh DMEM media and then equally divided in T75 flasks containing 10-15
ml media. Cells were then grown in CO2 incubator till 75-90% confluent.

Methods
Radiolabeled ([3H]) dopamine uptake assay
In order to determine if AMPH pre-treatment has an effect on the dopamine uptake and if the
effect persists in daughter cells after many cell divisions we performed [3H] dopamine uptake
assays.
Uptake Assays in LLC-PK1 cells
For each experiment a certain number of cells (150,000-300,000) were plated in
24wells/12wells/6wells plates. After 6 or 7 hours once the cells have adhered to the wells, one
set of cells were treated with 1µM or 50µM AMPH for 15 hours and the others served as control
(without treatment). After 15 hours, the drug was washed off with 1X PBS and after three
washes the cells were either taken to measure dopamine uptake after 15 hours of chronic AMPH
treatment or they were allowed to grow in fresh media and cross one/two/three cell divisions in
order to perform uptake assay in daughter cells. Uptake assay begins with washes with KrebsRinger HEPES (KRH) buffer. After removing media from the cells, each well is washed two
times with 1 ml of warm KRH buffer. After the washes, KRH buffer containing antioxidants and
monoamine oxidase inhibitors- 0.1mMTropolone, 0.1mM Ascorbic Acid and 0.1mM Pargyline

	
  

16	
  

(KRH+TAP), was added to wells to inhibit substrate degradation and the cells were incubated
with 20nM [3H] DA for 5 minutes. Following the incubation, the cells were washed with cold
KRH+TAP

3 times and lysed with 1%Triton. The lysates were collected in vials and

disintegration per minute (DPM) of [3H] dopamine in the lysates was counted using the βcounter.

Uptake Assays in SH-SY5Y cells
The experimental paradigm is similar to the experiments with LLC-PK1 cells where it starts with
plating a certain number of cells in 24wells/12wells/6wells plates and treating them with 1µM or
50µM AMPH for 15 hours after 6 or 7 hours once they have adhered to the wells. After 15 hours,
the drug was washed off with 1X PBS and after three washes the cells were either taken for
uptake assay to analyze dopamine uptake after 15 hours of chronic AMPH treatment or they
were allowed to grow in fresh media and cross one/two/three cell divisions, in order perform
uptake assay in daughter cells. The experiments with the SH-SY5Y cells involved one extra step
where we differentiated the cells with 10 µM RA in low serum media (DMEM containing 1%
FBS). After the cells crossed one/two/three cell divisions, they were subjected to RA induced
differentiation for 5 days. Cells were treated with 10µM RA twice over 5 days before performing
the [3H] dopamine uptake assay. Uptake assay begins with washes with Krebs-Ringer HEPES
(KRH) buffer. After removing media from the cells, each well is washed two times with 1 ml of
warm KRH buffer. After the washes, KRH buffer containing antioxidants and monoamine
oxidase inhibitors- 0.1mMTropolone, 0.1mM Ascorbic Acid and 0.1mM Pargyline (KRH+TAP),
was added to wells to inhibit substrate degradation and the cells were incubated with 20nM [3H]
dopamine for 5 minutes. Following the incubation, the cells were washed with cold KRH+TAP
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3 times and lysed with 1%Triton. The lysates were collected and disintegration per minute
(DPM) of [3H] dopamine in the lysates was counted using the β-counter.

Enzyme-linked Immunosorbent Assay (ELISA)
To ensure that AMPH was completely washed out after the 1hour treatment, an ELISA kit was
used to measure AMPH concentration in the cells prior to the uptake experiments.

The AMPH Direst ELISA Kit (Abnova, TW) consists of micro-wells coated with polyclonal
anti-d-AMPH, and d-AMPH conjugated to horseradish peroxidase (HRP). The principle of the
assay is based on the competitive binding of AMPH and AMPH-HRP in proportion to their
concentration in the reaction mixture. 10µl of the experimental sample is incubated with 100µl
dilution of enzyme (Horseradish peroxidase) labeled d-AMPH derivative in micro-plate wells
which are coated with fixed amounts of oriented high affinity purified polyclonal antibody. Since
it is a colorimetric assay, after removing the enzyme conjugate and washing the wells, a
chromogenic substrate is added. A dilute acid stop solution is added to cease the color produced
from the substrate and the absorbance in each well is read at 450 nm. The intensity of the color
developed is inversely proportional to the concentration of drug in the sample.

Before the assay cells were first detached with 1X trypsin and collected by centrifugation. Then
cells were washed with cold 1X PBS three times and re-suspended in PBS. The samples were
then sonicated (5 pulses for 5 seconds and then 10 pulses for 10 seconds) and subjected to
centrifugation at 1500Xg (4000 rpm) for 10 mins at 2-8º C to remove cellular debris.
Supernatants were collected and stored at -20°C or -80°C to avoid loss of bioactivity and

	
  

18	
  

contamination. When performing the assay, samples were brought to room temperature.

After collecting the samples, the assay was carried out. First 10µL of appropriately diluted
standards were added to wells (coated with polyclonal anti-d-amphetamine) in duplicate in a 96well plate. Then 10µL of cell lysates were added in duplicate in the 96-well plate. 100µL of the
AMPH-HRP conjugate was added to each well. To ensure proper mixing the sides of the plate
holder was tapped few times. The 96-well plate was incubated for 60 minutes at room
temperature in the dark (18-26°C), after addition of enzyme conjugate to the last well. The wells
were then washed 6 times with 200-350µL distilled water using either a suitable plate washer or
wash bottle.
After each wash the wells were inverted and dried on absorbent paper to ensure all residual
moisture is removed. This step is critical to ensure that residual enzyme conjugate does not skew
results. After that 100µL of substrate reagent was added to each well and properly mixed by
tapping the sides of the plate holder. After adding the substrate reagent, the plate was incubated
for 30 minutes at room temperature, preferably in the dark. After 30 minutes 100µL of Stop
Solution was added to each well, to change the blue color to yellow. The absorbance was then
measured at a wavelength of 450 nm within 1 hour of yellow color development.

Immunoblotting
In parallel to the uptake assays, we also investigated whether chronic exposure to AMPH in
progenitor cells alters the amount of DAT in daughter cells. We performed western blots in SHSY5Y cells to measure the total amount of DAT expressed in cells treated with AMPH with
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respect to control cells. As we proceeded with our investigation in the SH-SY5Y cells, we found
that the dopamine uptake was completely blocked by NET-specific inhibitor desipramine
whereas the DAT specific inhibitor GBR12935 failed to inhibit [3H] dopamine uptake at low
concentration (100nm). This suggested NET- mediated dopamine uptake in these cells and also
revealed that AMPH can induce its effect via NET. This prompted us to blot for NET protein in
daughter cells to determine any possible alteration in expression of NET in AMPH treated cells
vs control.

To see the effect of AMPH pretreatment in daughter cells, we allowed AMPH treated cells and
control cells to cross one/two/three cell divisions, before differentiating them with 10µM RA for
5 days. Following differentiation, the cells were lysed in 100µl - 400µl RIPA lysis buffer
containing protease inhibitors. The lysates were then centrifuged at 14,000 rpm for 10 minutes at
4°C to remove cellular debris. Supernatants were collected and then stored in -20°C. Prior to
western blots, the total amount of protein in the supernatants were quantified using BCA Protein
Assay Kit. The Thermo Scientific™ Pierce™ BCA Protein Assay is a detergent-compatible
formulation based on bicinchoninic acid (BCA) for the colorimetric detection and quantitation of
total protein.

Western Blots
Lysates of experimental samples were mixed with sample loading buffer (4:1 ratio) containing
5% 2-mercaptoethanol and performed SDS-PAGE in a 12% polyacrylamide gel. Proteins were
run in 1X tris-glycine running buffer at 120 Volts for 1.45 hours. Proteins were transferred in 1X
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transfer buffer at 4°C

and 35 Volts

for 1.45 hours to polyvinylidene difluoride (PVDF)

membranes. After transfer, membranes were blocked overnight by incubation with 3% bovine
serum albumin (BSA) in PBS-T (PBS plus 0.1% tween-20) at 4°C. Subsequent to blocking,
membranes were probed for 1 hour at RT with DAT specific goat polyclonal antibody (DAT
antibody, C-20) raised against amino acids 601 to 620 of the C-terminus of hDAT or NET
specific mouse monoclonal antibody (NET-human, NET17-1) raised against amino acids 17 to
33 of the N-terminus of hNET (1:1000 dilution in 3% BSA/PBS). The bound primary antibodies
were detected by incubating the membranes for 1 hour at room temperature with anti-goat or
anti-mouse IgG secondary (2°) antibody linked to alkaline phosphatase (1:5000 dilution in 3%
BSA/PBS). After each antibody treatment, membranes were washed 5 times with PBS-T. In
order to develop the blot, membranes were incubated in 3 ml alkaline phosphatase substrate for 5
minutes. The membranes were sandwiched between plastic film and imaged on Omega Lum™ G
Imaging System and quantified using Adobe Photoshop software.

Materials used
Reagents
Phosphate Buffer Saline (1.37 M Sodium chloride, 2.7 mM Potassium chloride, 100mM
disodium phosphate, 18mM potassium di-hydrogen phosphate, pH 7.4). Krebs-Ringer HEPES
buffer (116 mM Sodium chloride, 4mM Potassium chloride, 1mM Magnesium chloride, 1.8 mM
Calcium chloride, 25 mM Glucose, 10mM Hepes, pH 7.4). RIPA lysis buffer (20 mM Tris, 150
mM NaCl, 1mM Na3VO4 , 10 mM NaF, 1mM EDTA , 1mM EGTA, 1% Triton, 0.1% SDS,
0.5% deoxycholate, pH-7.4). 1X Transfer buffer (25 mM Tris, 192 mM glycine, 0.1% SDS; 20%
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methanol). SDS-PAGE 10X gel running buffer (248 mM Tris, 1.92 M glycine, 1% w/v SDS);
the 10X buffer is diluted to 1X for running SDS-PAGE gels.

DMEM and Penicillin/Streptomycin media were from Thermo Fisher Scientific (Waltham, MA,
USA); EMEM, G418 sulfate, 1X Trypsin, Antibacterial and Antimycotic and L-Glutamine were
from Corning Cellgro (Manassas, VA, USA); FBS was from Atlanta Biologicals (Atlanta, GA,
USA); Glucose, AMPH, and anti-mouse IgG 2° antibody linked to alkaline phosphatase were
from Sigma Aldrich (St. Louis, MO, USA); DAT specific goat polyclonal antibody raised
against amino acids 601 to 620 of the C-terminus of hDAT and anti-goat IgG 2° antibody linked
to alkaline phosphatase were from Santa Cruz Biotechnology (Dallas, TX, US); Dimethyl
Sulfoxide (DMSO), Sucrose, HEPES, EDTA, Protease Inhibitor Tablets, Tween-20, Triton X100, Sodium Deoxycholate, Sodium Chloride, Sodium Fluoride, BSA, Sodium Phosphate,
Potassium Chloride, Disodium Phosphate, Calcium Chloride, Potassium Dihydrogen Phosphate,
SDS, Methanol, Glycine, 2-Mercaptoethanol, Tris-HCl, DTT, and PVDF membranes were from
Fisher Scientific (Waltham, MA, USA); Alkaline phosphatase substrate (ImmunStar) was from
Bio-Rad (Hercules, CA, USA).
Equipment
Transfected LLC-PK1 cells and SH-SY5Ycells were maintained in a Nuair 2700-30 water
jacketed CO2 incubator and handled in a Nuair class II type A/B3 class II biological safety
cabinet laminar flow hood. The cellular lysates for ELISA and western blots were centrifuged
using an Eppendorf micro centrifuge 5424R. Cellular pellets were solubilized using a
Bransonic® water bath sonicator. Cell membranes were assayed for protein content using Epoch
microplate reader from Biotek. SDS-PAGE and protein transfer to PVDF membranes was
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performed using Mini-Protean tetra electrophoresis apparatus and Mini trans-blot electrophoretic
transfer cell respectively from Bio-Rad. The power supply used to control both the
electrophoresis apparatus and electrophoresis transfer cell was also from Invitrogen.
Illuminescence from PVDF membranes were imaged using an Omega Lum™ G Imaging System
and quantified using Adobe Photoshop software. All statistical analyses were done using
graphpad prism software. Chemical reagents were measured on analytical balance from Ohaus.
Disintegration per minute (DPM) of [3H] dopamine in experimental samples were counted using
LS 6500 multi-purpose scintillation counter from Beckman.

RESULTS
Chronic AMPH exposure causes long term effect on dopamine uptake in hDAT expressing LLCPK1 cells
AMPH is known to cause a down-regualtion of DAT activity, as well as NET and SERT
functions. AMPH causes an elevation in synaptic concentration of dopamine by preventing
neurotransmitter uptake by competitively binding to DAT and promoting dopamine efflux via
reverse activity of the transporter.

Studies have shown that AMPH targets DAT, among many other proteins, to promote elevated
dopamine transmission and previous work done in our lab demonstrated that in the long run
AMPH treatment reduces dopamine uptake by acting on the transporter in the model organism
C.elegans . To find out if the effect we observed in C.elegans is reproducible in hDAT
expressing cells and to focus on the effect of AMPH on hDAT, initial experiments were done in
LLC-PK1 cells stably expressing hDAT.
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In our initial experiments with LLC-PK1, cells were with 1µM or 50 µM AMPH for 15 hours
and then dopamine uptake was measured by [3H] dopamine uptake assays. We also measured
dopamine uptake following 15 hrs of AMPH treatment after the cells have undergone one, two
and three cell divisions.

When treated with 1µM AMPH the results show a significant reduction of 20% in dopamine
uptake in treated cells with respect to control after 15 hours of treatment (Figure- 7A). However,
this significant decrease in dopamine uptake was not maintained in daughter cells as we saw no
significant change in dopamine uptake between AMPH treated cells and control after one, two,
and three cell divisions (Figure- 7B, 7C, 7D).

When cells were treated with much higher concentration of 50 µM AMPH, the results show a
significant reduction of 35-40% in dopamine uptake in AMPH treated cells with respect to
control (cells without treatment) after 15hrs of AMPH treatment (Figure-8A). This effect was
transmitted and maintained in daughter cells up to at least three cell divisions where we saw a
similar percent reduction (~40%) in dopamine uptake in treated cells (Figure- 8B, 8C, 8D). We
used GBR12935 as a selective DAT inhibitor to validate that the dopamine uptake was solely
mediated by DAT.
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A. After 15 h of AMPH treatment

B. One cell division after AMPH treatment

C. Two cell divisions after AMPH treatment

D. Three cell divisions after AMPH treatment

Figure 7: AMPH concentration of 1µM causes reduced dopamine uptake in hDAT expressing
LLC-PK1 cells after (A) 15 hrs of treatment but the significant reduction was not maintained after
(B) one cell division, (C) two cell divisions, and (D) three cell divisions. 10µM GBR12935
completely blocked dopamine uptake validating the uptake we observed was specific to DAT.
Statistical analyses were done by one-way ANOVA and Bonferroni's Multiple Comparison test,
p<0.05, using Graphpad Prism software (version 5). Histograms represent dopamine uptake
expressed as mean± SE of controls set to 100%, where ***= p<0.001.
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A. After 15 h of AMPH treatment

B. One cell division after AMPH treatment

C. Two cell divisions after AMPH treatment

D. Three cell divisions after AMPH treatment

Figure 8: AMPH treatment of 50 µM causes reduced dopamine uptake in hDAT expressing
LLC-PK1 cells after (A) 15 hrs of treatment, (B) after one cell division, (C) after two cell
divisions, and (D) three cell divisions. 10µM GBR12935 completely blocked dopamine uptake
validating the uptake we observed was specific to DAT. Statistical analyses were done by oneway ANOVA and Bonferroni's Multiple Comparison test, p<0.05, using Graphpad Prism
software (version 5). Histograms represent dopamine uptake expressed as mean± SE of controls
set to 100%, where ***= p<0.001.
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AMPH-induced reduction of dopamine uptake in SH-SY5Y cells is maintained in daughter cells
From our initial experiments in LLC-PK1 cells, we found that AMPH treatment for 15hrs
significantly reduces dopamine uptake in parent cells and this effect was transmitted and
conserved up to at least three cell divisions where we saw similar percent reduction in dopamine
uptake in daughter cells. These data led us to hypothesize that chronic AMPH treatment causes
long term reduction in dopamine uptake by down-regulating the expression or activity of DAT.

To further test our hypothesis, we moved on from a heterologous system artificially
overexpressing DAT to a cell line which brought us closer to the physiology of human
dopaminergic neurons. In our next approach, we used the human neuroblastoma cell line- SHSY5Y. SH-SY5Y cells have been used frequently, either in an undifferentiated state, or in a
neuron-like differentiated state after induction with retinoic acid (RA). RA treatment has been
shown to induce the expression of tyrosine hydroxylase (TH), suggesting a shift towards a DA
neurotransmitter phenotype. Based on literatures the neuroblast-like morphology of these cells
are not only positive for TH but also for dopamine-β-hydroxylase, the enzyme which is known
to catalyze the conversion of dopamine to norepinephrine. Hence, SH-SY5Y has been used as a
dopaminergic as well as a noradrenergic model system.

For our experiments, we took advantage of the neuronal characteristics of these cells and the
endogenous expression of monoamine transporters (DAT, NET, SERT). We repeated the same
experiments using SH-SY5Y to determine if the long term behavioral effects of AMPH we
observed in C.elegans and in the initial experiments with LLC-PK1 is reproducible. The
experimental paradigm is similar where we pretreated SH-SY5Y cells with 1µM or 50 µM
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AMPH or control solution for 15 hours. The cells were then washed three times to remove
AMPH and allowed to undergo cell division(s). For one set experiments we performed uptake
assays immediately after 15hours of AMPH treatment and for the rest of the experiments, after
the cells crossed cell division(s) they were subjected to RA-induced differentiation for 5 days.
After 5 days of differentiation [3H] dopamine uptake assays were carried out to measure
dopamine uptake in daughter cells.

Uptake assays carried out after 15 hours of chronic 1µM AMPH treatment showed a significant
reduction of 24% in dopamine uptake in AMPH treated cells with respect to cells without
treatment (control) (Figure-9A) but the effect was not maintained after one, two, and three cell
divisions (Figure- 9B, 9C, 9D).This result matched our initial experiments with LLC-PK1 cells.
Results from these experiments also revealed NET mediated dopamine uptake in these cells.
When 100nM of GBR12935 was used to selectively block DAT, it failed to inhibit dopamine
uptake. Since we obtained a robust dopamine uptake in these cells, we tested whether dopamine
was reaccumulated via the other monoamine transporter NET, by adding a specific NET
inhibitor-desipramine. We found that 100nM of desipramine completely blocked dopamine
uptake (Figure 9 and 10) suggesting that the uptake is mostly mediated by NET in SH-SY5Y
rather than DAT.

When the same experiments were repeated with 50 µM AMPH treatment for 15 hours, we saw a
reduction of 45% in treated cells with respect to control (Figure- 10A). As the goal of these
experiments were to determine if the effect of chronic AMPH treatment persists in daughter cells
after many cell divisions, we performed uptake assays after one, two and three cell divisions. Our
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results show a similar reduction of 45-50% in dopamine uptake in AMPH treated group vs
control after cell division(s) (Figure- 10B, 10C, 10D). The complete inhibition of dopamine
uptake by desipramine was seen repeatedly in all these experiments, validating that it is a NET
mediated uptake and also suggesting that AMPH can induce its effect not only via DAT but also
through other monoamine transporters like NET.

While performing the uptake assays, the cell count and cell viability were monitored in AMPH
treated group and control to ensure AMPH treatment does not have a toxic effect on cell growth.
In every experiment cells were counted prior to uptake assay and results show that there is no
significant difference in cell number or viability between treated cells and control (Figure-11)
validating that the AMPH induced decreased dopamine uptake we observed was not due to a
decrease in cell viability in treated cells.
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A. After 15 h of AMPH treatment

B. One cell division after AMPH treatment

C. Two cell divisions after AMPH treatment

D. Three cell divisions after AMPH treatment

Figure 9: AMPH at a concentration of 1 µM causes reduced dopamine uptake in SH-SY5Y cells
(A) 15 hrs after treatment but the effect was not maintained in RA differentiated SH-SY5Y cellsafter (B) one cell division, (C) two cell divisions, and (D) after three cell divisions. 100nM
GBR12935 failed to block dopamine uptake whereas the same concentration of desipramine
(Desp.) inhibited the uptake, validating that the dopamine uptake we observed was moreso
specific to NET than DAT. Statistical analyses were done by one-way ANOVA and Bonferroni's
Multiple Comparison test, p<0.05, using Graphpad Prism software (version 5). Histograms
represent dopamine uptake expressed as mean± SE of controls set to 100%, where ***= p<0.001.
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A. After 15 h of AMPH treatment

B. One cell division after AMPH treatment

C. Two cell divisions after AMPH treatment

D. Three cell divisions after AMPH treatment

Figure 10: AMPH treatment of 50 µM causes 45-50% reduction in dopamine uptake in SHSY5Y cells (A) 15 hrs after treatment. A similar percentage (45-50%) reduction was observed in
RA differentiated SH-SY5Y cells after (B) one cell division, (C) two cell divisions, and after (D)
three cell divisions. 100nM GBR12935 failed to block dopamine uptake whereas the same
concentration of desipramine (Desp.) inhibited the uptake, validating that the dopamine uptake
we observed was moreso specific to NET than DAT. Statistical analyses were done by one-way
ANOVA and Bonferroni's Multiple Comparison test, p<0.05, using Graphpad Prism software
(version 5). Histograms represent dopamine uptake expressed as mean± SE of controls set to 100%,
where ***= p<0.001.
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A. After 15 h of AMPH treatment

B. One cell division after AMPH treatment

C. Two cell divisions after AMPH treatment

D. Three cell divisions after AMPH treatment

Figure 11: Cell count on the day of the experiments revealed no significant difference in cell
number or viability between AMPH treated and control (A, B, C, D). Cell viability was between
99-100% in both groups. Statistical analyses were done by unpaired t-test, p<0.05, using
Graphpad Prism software (version 5) and there was no significant difference between the two
groups.
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ELISA to detect AMPH revealed very low concentration of AMPH remaining in the cells prior
to the uptake assay
The goal of our project was to establish that the effect of AMPH treatment on the catecholamine
transporters is transmitted to daughter cells. In order to ensure that AMPH was completely
washed out after 15 hours of treatment and by the time we performed our uptake assay, we used
an ELISA kit to measure AMPH concentration in the cells prior to the uptake experiments.

Our results revealed very low levels of AMPH in treated cells which was close to the background
concentration we measured in control cells (Table-1). These results validated that the decrease in
dopamine uptake we measured in AMPH treated cells was not due to the presence of AMPH
during the uptake assays.
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Table 1: Very low-levels of AMPH was left over in cells prior to the uptake assays

Conc.(ng/ml)

Conc. (fM)

Control

3.03±0.78

6.47

AMPH

6.51±1.59

13.8

ELISA results showing concentration of AMPH remaining in AMPH treated cells after cell
division(s). Initially cells were treated with 50µM AMPH and then the drug was washed off after
15 hours of treatment. Cell lysates for ELISA were collected prior to uptake assays from both
groups (treated and untreated). Very low concentration of AMPH was measured by ELISA
which was close to the background concentration in untreated cells.
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DAT protein expression in daughter cells following chronic AMPH treatment in progenitor cells
We hypothesized that AMPH induces long term reduction in dopamine uptake by downregulating the activity or expression of DAT. Hence in parallel to the uptake assays done in SHSY5Y cells, we also investigated whether chronic exposure to AMPH in progenitor cells alters
the amount of DAT in daughter cells.

To look at DAT protein expression, we collected cell lysates from SH-SY5Y cells treated with
50 µM AMPH or vehicle for 15 hours before being differentiated with RA for 5 days. Cells were
lysed in 100-400µl RIPA buffer and used for western blot analysis to determine DAT protein
expression. We immunoblotted against the DAT protein using a DAT specific goat polyclonal
antibody raised against amino acids 601 to602 of the C-terminus of hDAT. DAT levels were
corrected for loading using Actin as a loading control. We blotted for β-Actin using a mouse
monoclonal antibody raised against a recombinant protein corresponding to a region near the Cterminus of β-Actin of human origin. From our results we observed no significant difference in
the total amount of DAT expressed in AMPH treated cells with respect to control cells (Figure
12).
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Figure 12: Western blot results showing no significant difference in DAT protein expression
between AMPH treated cells and control, following chronic AMPH treatment in progenitor cells.
Membranes were probed with DAT specific goat polyclonal antibody (1:1000 dilution in 3%
BSA/PBST) and the bound antibodies were detected with anti-goat IgG secondary antibody
linked to alkaline phosphatase (1:5000 dilution in 3% BSA/PBST). Statistical analyses were
done by unpaired t-test, p<0.05, using graphpad prism software
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DISCUSSION
The abuse of drugs can be split into categories which include illicit use of prescription drugs or
use of illegal drugs that mostly rises from the inability to stop seeking drugs that ultimately leads
to drug tolerance or physiological dependence. The possible pleasurable effects achieved from
the abuse of psychostimulants are often the reason behind possible incremental increase in drug
intake and gradual development of addiction to the substance.

AMPH is widely recognized for its role in treating ADHD, narcolepsy, chronic fatigue
depression and several other disorders but despite its important medicinal role, AMPH and its
analogues are highly abused illicit drugs all over the world. One of the primary molecular targets
of AMPH, and its derivatives like methamphetamine, are the monoamine transporters. AMPH is
known to induce excess extra-neuronal dopamine concentration by promoting dopamine
efflux[27].

The use of AMPH in ADHD is a long term treatment and people taking AMPH for prolonged
periods of time often develop addiction over months and sometimes for years. Popular
prescription AMPHs like Adderall are often assumed to be safe as they are prescribed by doctors
but abuse of Adderall can lead to an addiction that can be hard to break. Previous studies have
illustrated the mechanism of how AMPH works on the monoamine transporters to induce
dopamine efflux but very few studies have investigated the long term consequences of AMPH
use.
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The general interest of our lab is to look at changes happening from drug exposure, in the long
term and across generations. Previous work done in the lab has already found that exposing
C.elegans to AMPH during embryogenesis induces behavioral changes in adult worms. It has
been found that in C.elegans, an excess of extracellular dopamine results in loss of motility in
fluid- a behavioral phenotype termed ‘swimming induced paralysis’ (SWIP). Using SWIP assay
it was shown that adult worms who were exposed to AMPH as embryos show increased SWIP
when challenged with AMPH with respect to control groups (animals who never saw the drug).
These data suggest that the animals have a memory of the drug exposure during their
developmental stage. Even though the worms were only exposed to AMPH as embryos and
never saw the the drug again, the exposure during development had a long term effect which
resulted in increased SWIP behavior at a much later stage in the worm’s life.

Since DAT is one of the major proteins which is targeted by AMPH to induce SWIP in
C.elegans[28], we investigated the long term effect of AMPH in hDAT expressing cells, to
determine if the effect of AMPH on C.elegans DAT is reproducible with hDAT. For our initial
experiments, we worked with LLC-PK1 cells which were stably transfected with hDAT. This
helped us determine the effect of AMPH on dopamine uptake by the transporter over long term.
We treated cells with two different concentrations of AMPH, 1µM and 50 µM, for 15 hours and
performed [3H] dopamine uptake assays after cell division(s). We know that for therapeutic
purpose AMPH is prescribed in few µM range (1-10µM) but when abused the concentration is
much higher. Hence, we chose to investigate AMPH induced effect on dopamine uptake once
with a low concentration treatment (1µM) and then with a higher concentration of 50 µM[29].
Our results show a significant decrease in dopamine uptake in treated cells compared to
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untreated cells when we performed uptake assay immediately after 15 hours of AMPH treatment.
This significant reduction in dopamine uptake was transmitted and maintained in daughter cells
after one, two and three cell divisions when 50 µM AMPH was used. These results demonstrated
that the long-term effect we observed in C.elegans is reproducible in hDAT expressing cells.
Since these experiments were done in a heterologous system, artificially over-expressing DAT,
the results also helped us verify that AMPH induces a decrease in dopamine uptake by acting on
the transporter either by down-regulating DAT expression on the cell surface or by impairing
DAT activity to uptake dopamine.

To further test our hypothesis we repeated similar experiments in the human neuroblastoma cells,
SH-SY5Y. These cells have an endogenous expression of monoamine transporters (DAT, NET,
and SERT) and exhibit neuronal characteristics. The use of SH-SY5Y cells helped us mimic the
experiments done in C.elegans where AMPH treatment during embryogenesis caused behavioral
changes in adult worms. The results suggests that the presence of AMPH during the
developmental stage has an effect on the neuronal precursor cells that later develop into
dopaminergic neurons in C.elegans and we see a consequence of that at a much later stage in the
worm’s life. In the case of the SH-SY5Y cells, we treated the cells with AMPH before inducing
differentiation with RA to determine if AMPH pre-treatment prior to differentiation, when
neuronal precursor cells are present, induce a similar decrease in dopamine uptake in the long
term.

Our experimental paradigm included treating cells with AMPH for 15 hours and differentiating
the cells with RA once they have crossed cell division(s), followed by the uptake assay. Our data
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revealed that dopamine uptake in differentiated SH-SY5Y cells were mostly mediated by NET
instead of DAT which was significantly reduced in AMPH treated cells with respect to control
cells up to three cell divisions. We ensured that the decrease in dopamine uptake in daughter
cells was not due to the presence of AMPH during the uptake assays, by performing ELISA
against AMPH which displayed very low concentration of AMPH left-over in cells that was
close to the background concentration measured in untreated cells. Taken together, these data
suggest that ‘chronic AMPH treatment causes long term reduction in dopamine uptake via downregulation of expression or activity of monoamine transporters like DAT and NET’.

With the SH-SY5Y cells we further investigated the expression of total DAT protein in daughter
cells following AMPH treatment in progenitor cells and observed no significant difference in the
total amount of DAT expressed in treated group with respect to control. This could imply several
prospects like – (a)AMPH pre-treatment induces long term decrease in dopamine uptake not by
altering the total transporter expression but via altering DAT expression only on the cell surface;
(b) AMPH pre-treatment does not alter the number of DAT on the cell surface but downregulates its capability to uptake dopamine from the synapse; (c) as we found out from the
experiments with the SH-SY5Y cells that the dopamine uptake in these cells is dominated by
NET, AMPH pre-treatment can decrease NET expression on the cell surface or impair its
activity, both of which culminates in decreased dopamine uptake.
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CONCLUSION
AMPH is a potent CNS stimulant and is widely known for its addictive properties. Several
studies have already shown that chronic AMPH treatment promotes increased monoamine
transmission and decreases their uptake into the presynaptic neuron but very few studies have
investigated the possibility of this effect to persist in the long term. The unique aspect of our
investigation is we were able to show how AMPH induced reduced dopamine uptake in parent
cells is transmitted to daughter cells in the absence of the drug. The cells had a memory of the
treatment and the effect was maintained up to three cell divisions. Since AMPH is one of the
most effective drugs to treat children and adolescents with conditions like ADHD, evidences
indicating a long term effect from the use of the drug should be deemed important when
considering AMPH’s therapeutic use and should be further investigated.
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